-$0.31 EPS Expected for Mersana Therapeutics, Inc. (NASDAQ:MRSN) This Quarter

Brokerages expect Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) to report earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from ($0.65) to ($0.09). Mersana Therapeutics reported earnings per share of ($0.50) during the same quarter last year, […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Canada ,Hong Kong ,Texas ,United States ,Timothyb Lowinger ,Thomson Reuter ,Upifitamab Rilsodotin Upri ,Mikhail Papisov ,Securities Exchange Commission ,Zacks Investment Research ,Ensign Peak Advisors Inc ,Mersana Therapeutics Inc ,Nasdaq ,Hong Kong Ltd ,Royal Bank ,Mersana Therapeutics ,Get Rating ,Mersana Therapeutic ,Investment Research ,Exchange Commission ,Director Andrew ,Peak Advisors Inc ,Kong Ltd ,Retirement System ,Amalgamated Bank ,Upifitamab Rilsodotin ,Nasdaq Mrsn ,Mrsn ,Medical ,Ratings ,Consensus ,